Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01796626 · ClinicalTrials.gov registry record · NA
Clinical Evaluation of M22 ResurFX 1565nm Module
A NA study, sponsored by Lumenis Be.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT01796626 is a NA study that has completed, run by Lumenis Be. The registered enrollment target is 36 participants.
The verdict
NCT01796626, a NA study, has completed, sponsored by Lumenis Be.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
At least thirty (30) subjects, Fitzpatrick-Goldman Skin Type I-IV will be enrolled in 2 clinical sites; each clinic will enroll at least 15 subjects. Subjects should present visible wrinkles and/or striae requiring treatment. Hypothesis: The M22 ResurFX 1565nm module will improve the appearance of the wrinkles by at least 2 grades on the Fitzpatrick-Goldman Wrinkle and Elastosis Score, and striae by at least 50% using VAS as compared to baseline, for at least 75% of the subjects.
Interventions
- DEVICE M22 ResurFX module
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01796626
The ClinicalTrials.gov registry entry for NCT01796626 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lumenis Be, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which M22 ResurFX module is the first listed.
NCT01796626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01796626 about?
NCT01796626 is a clinical study titled "Clinical Evaluation of M22 ResurFX 1565nm Module". At least thirty (30) subjects, Fitzpatrick-Goldman Skin Type I-IV will be enrolled in 2 clinical sites; each clinic will enroll at least 15 subjects. Subjects should present visible wrinkles and/or striae requiring treatment. Hypothesis: The M22 ResurFX 1565nm module will improve the appearance of...
What is the current status of trial NCT01796626?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2012-12. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01796626?
The interventions under investigation include: M22 ResurFX module (DEVICE).
Who is sponsoring clinical trial NCT01796626?
This trial is sponsored by Lumenis Be, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.